Stifel reiterates Glaukos stock rating on regulatory optimism

Glaukos received reiterated Buy coverage and a $170 price target from Stifel after a regulatory meeting that increased confidence in looser LCD step-therapy requirements for iDose. The company also reported Q1 2026 EPS of -$0.18 versus -$0.28 expected and revenue of $150.6 million versus $137.04 million expected, up 41% year over year. BTIG and Needham both raised targets to $162 and $136, respectively, reinforcing bullish sentiment despite a slight after-hours dip.

Analysis

GKOS is becoming a classic regulatory beta-to-fundamentals setup: the market is starting to price not just incremental reimbursement probability, but a change in the adoption curve for the entire glaucoma surgery category. If step-therapy language loosens, the marginal payer-approved patient pool expands, which matters more than the near-term earnings beat because it can pull forward procedure volumes for multiple quarters rather than simply lift one print. The real second-order effect is on surgeons and ambulatory centers: easier coverage lowers friction for earlier intervention, which should raise utilization rates for premium device platforms and improve evidence generation, creating a self-reinforcing loop.

The setup also has a meaningful dispersion angle. A favorable LCD outcome would disproportionately help differentiated procedure-based names and likely pressure incumbents tied to chronic drop therapy, because the policy debate is implicitly about the limitations of first-line pharmacologic management. That said, the market may be underestimating timing risk: even if the signal is positive, implementation can lag by 1-2 quarters, and the stock is already discounting a good chunk of the optimistic case. In other words, the next leg is more likely to come from reimbursement language specificity than from another upside earnings surprise.

The main contrarian risk is that investors are extrapolating a binary policy win into a linear growth trajectory. If the final LCD preserves enough ambiguity around “or” versus “and,” or if local contractors soften the language without materially changing coverage behavior, the multiple can compress quickly because the stock has already re-rated on sentiment. Also, the company’s operating leverage means any disappointment on procedure mix or commercialization cadence will hit valuation hard; this is a high-expectations setup, not a deep value rerating.

For trading, the best risk/reward is to own the catalyst with defined downside rather than chase spot strength. The opportunity is less about direction and more about convexity: a modestly positive policy change could justify another 10-20% rerating, while a neutral outcome may give back a meaningful portion of the recent move. Position sizing should reflect that this is a multi-month regulatory trade with event risk concentrated around policy commentary rather than earnings.

Key Decisions for Investors

• Initiate a tactical long GKOS position into regulatory follow-through, with a 4-8 week horizon; target a 10-15% upside re-rating if LCD language improves, but keep a tight 6-8% stop on any indication the policy remains unchanged.
• Buy GKOS call spreads 1-2 quarters out to express upside convexity with limited premium burn; prefer strikes just above spot to avoid paying for the already-rerated base case.
• Pair trade: long GKOS / short a mature glaucoma-drug exposure or broader ophthalmology peer basket to isolate a coverage-driven adoption shift; thesis works if reimbursement loosens while chronic drop economics remain pressured.
• If GKOS fails to hold recent gains on follow-up policy headlines, reduce exposure quickly rather than waiting for earnings; the stock is more vulnerable to policy disappointment than to operational weakness in the near term.